Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | JAK1 L653F |
Therapy | Ruxolitinib |
Indication/Tumor Type | hematologic cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
JAK1 L653F | hematologic cancer | sensitive | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Jakafi (ruxolitinib) inhibited Stat5 phosphorylation and viability in a cell line expressing JAK1 L653F in culture (PMID: 36786170). | 36786170 |
PubMed Id | Reference Title | Details |
---|---|---|
(36786170) | SOCS3 deregulation contributes to aberrant activation of the JAK/STAT pathway in precursor T-cell neoplasms. | Full reference... |